AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 25 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The retinoid isotretinoin offers little benefit to HIV[superscript]+ women with precancerous cervical lesions, researchers in the United States argue.
William R. Robinson and colleagues at Texas Tech University's Harrington Cancer Center in Amarillo evaluated isotretinoin's ability to prevent low-grade, benign cervical lesions from progressing to high-grade or malignant lesions during HIV infection.
Although the researchers did uncover some good news for HIV[superscript]+ women, they also found that isotretinoin failed to provide them with significant protection from cervical lesion progression.
Female HIV patients with low-grade squamous intraepithelial lesions (SIL) of the cervix were received either 0.5 mg/kg daily doses of isotretinoin or observation for 6 months, according to the report. Usually used to treat severe acne, isotretinoin - like most retinoids - can also be used to help regulate cell growth and differentiation.
However, the risk of developing high-grade cervical SILs was not significantly lower for isotretinoin-treated women than for control patients, with progression rates around 20% in both cohorts, study data showed. Women 30 years of age or younger had significantly higher risk of lesion progression although CD4 cell counts had little or no effect on progression risk.
None of the study ...